MedTrace Logo

Caris Chromoseq Data Collection

NCT07680868 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-07-02

No results posted yet for this study

Summary

The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.

Conditions

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
  • Myelodysplatic Syndromes
  • Myeloproliferative Neoplasm

Interventions

DIAGNOSTIC_TEST

Caris Chromoseq

The Caris Chromoseq assay is designed to provide whole genome profiling of hematologic malignancies in the human genome. Various internal studies have been performed that validate the performance of these genetic alterations including SNVs, CNAs, INDELs, and SVs in AML, MDS, and MPN.

Sponsors & Collaborators

  • Caris Science, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2029-07-31
Completion
2029-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680868 on ClinicalTrials.gov